PHP Sweetens Bid for Rival Assura as It Seeks to Unseat KKR
Primary Health Properties Plc has made a revised cash and share offer for rival healthcare landlord Assura Plc that values the company at about £1.68 billion ($2.2 billion).
The company's bid implies a total value of 51.7 pence for each Assura share, a 4.7% premium to the cash deal from KKR & Co. and Stonepeak Partners that's been recommended to shareholders, according to a statement Friday. The offer is comprised of 0.3769 new PHP shares and 12.5 pence in cash for each Assura share, it said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading session saw CRISPR Therapeutics AG (CRSP) ending at $42.94, denoting a +2.02% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 0.55%. At the same time, the Dow added 0.25%, and the tech-heavy Nasdaq gained 0.63%. Shares of the company have appreciated by 11.97% over the course of the past month, outperforming the Medical sector's gain of 3.49% and the S&P 500's gain of 6.29%. Investors will be eagerly watching for the performance of CRISPR Therapeutics AG in its upcoming earnings disclosure. On that day, CRISPR Therapeutics AG is projected to report earnings of -$1.54 per share, which would represent a year-over-year decline of 3.36%. At the same time, our most recent consensus estimate is projecting a revenue of $5.89 million, reflecting a 1032.88% rise from the equivalent quarter last year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$5.54 per share and revenue of $39.95 million, indicating changes of -27.65% and +7.06%, respectively, compared to the previous year. It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. These revisions typically reflect the latest short-term business trends, which can change frequently. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, there's been a 1.68% fall in the Zacks Consensus EPS estimate. CRISPR Therapeutics AG is currently a Zacks Rank #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 76, placing it within the top 31% of over 250 industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Geek Vibes Nation
35 minutes ago
- Geek Vibes Nation
How ChatGPT Bots Handle Client DMs While I Sleep – And Land Me New Deals
A good fit Ready to start Needing more info' This prompt works with DM automation tools that support branching logic. I collect info while I sleep – and wake up knowing which leads are warm. Claude Prompt #6 – Turn Chat Transcripts Into CRM Notes Prompt: 'Summarize this DM chat into 3 bullet points for my CRM: Who they are What they need How to follow up' This is huge when you're juggling 20 conversations. Claude acts like a personal assistant that cleans up your notes, flags key info, and saves it to Notion, Airtable, or whatever you use. AI DM Bot Comparison Use Case Best Model Why It Works Warm intro DM ChatGPT Fast, friendly, low-friction copy Deep context follow-up Claude Reads nuance and builds trust FAQ automation ChatGPT Clear, reusable, scalable replies Lead qualification Claude Detects readiness, helps filter CRM note generation Claude Great for summarizing long convos The Real Win – Focus on Closing, Not Replying Since I implemented this ChatGPT + Claude + Chatronix setup, I spend less time chasing leads and more time closing deals. I don't lose prospects because I replied too late. I don't drop the ball on follow-ups. And I don't miss qualified leads buried in my DMs. It's not about automating relationships – it's about automating friction so real connection can happen. Want your DMs to work while you rest? ✅ Visit Chatronix and set up your dream AI sales assistant – without hiring anyone. Emily Henry writes for UKWritings Reviews and Write My Research Paper . She writes articles on many subjects including writing great resumes. Emily is also an editor at State Of Writing .
Yahoo
an hour ago
- Yahoo
GM says it will invest $4 billion to increase US production
General Motors said on Tuesday that it would invest $4 billion into three US plants to boost production of gas and electric vehicles, as a 25% tariff on imported cars by President Donald Trump threatens the bottom lines of automakers that sell in the United States. It was not immediately clear how much of the $4 billion had already been announced or committed. The automaker's plan reflects the rush by manufacturers to invest in the United States to sidestep Trump's tariffs – or at least to make splashy, eye-catching announcements that could win them a reprieve. GM CEO Mary Barra previously told CNN that the 25% tariff on cars (and on imported auto parts) would cost the company between $4 billion and $5 billion in 2025. Trump has levied tariffs on several sectors, including a 50% tariff on steel and aluminum that also could hurt automakers, as well as 10% tariffs on US trading partners generally. But he's also paused, increased, walked back and modified many of his tariffs, leading to confusion among investors, importers and businesses that are trying to figure out how to stay afloat. The GM investment will go into three locations, the company said in a release: Orion Assembly in Orion Township, Michigan; Fairfax Assembly in Kansas City, Kansas; and Spring Hill Manufacturing in Spring Hill, Tennessee. GM's contract with the United Auto Workers in 2023 promised an additional investment in both the Orion and Fairfax assemblies. The contract does not mention a Spring Hill investment. 'Today's announcement demonstrates our ongoing commitment to build vehicles in the US and to support American jobs,' Barra said in GM's statement. GM spokesman Kevin Kelly said the investment announced Tuesday was in addition to the additional investment that the company had promised to make as part of its 2023 labor agreement with the United Auto Workers union. GM's announcement did not say the company was shifting any production from its foreign auto plants to the United States, although the gasoline-powered version of the Blazer, which will now be built in Spring Hill, Tennessee, is current built in Mexico. It had previously announced that it was increasing production of the Silverado pickup at its Fort Wayne, Indiana, plant, but it did not announce plans to cut Mexican or Canadian production of those best-selling pickup trucks. In 2024, GM built nearly 1 million cars in Canada and Mexico, according to figures from S&P Global Mobility, compared to 1.7 million it built at US factories. Most of those Mexican and Canadian built cars were shipped to GM's US dealerships. It also imported an additional 415,000 cars it built in South Korea to US dealerships, with about half of those sales the Trax compact SUV. And it imported 47,000 Buick Envision SUVs from China. Other than the gasoline-powered Blazer, of which it sold about 53,000 last year, GM has no immediate plans to shift foreign production to US facilities, Kelly said. The United Auto Workers union praised GM's move – and Trump's use of tariffs. 'While other companies drag their feet, GM is showing that strategic auto tariffs work with a massive $4 billion investment that will create thousands of good paying union jobs,' UAW President Shawn Fain said in a statement. 'It's time to invest in blue collar America, and GM is showing how it's done. This is just the beginning.' Trump has been vocal in demanding companies move production to the United States, one of the stated goals of his tariff campaign, which will touch products across a broad swath of American life. GM was the first major company to estimate a dollar amount for its costs from Trump's sweeping tariffs. Many other companies have walked back earnings forecasts because of the ensuing economic uncertainty or have said they will likely raise prices at some point this year. Ford, for example, said it expects to raise its US car prices as much as 1.5% in the second half of 2025 due to the import levies. While GM is not the dominant global auto player it once was, it is still the largest automaker in terms of American sales, with 2.7 million cars and trucks sold in the US last year. And all of those cars and trucks, not just the imports, are vulnerable to Trump's tariffs to some extent. Even the 1.7 million cars and trucks GM built in the US last year depended on imported parts to some degree (although some of the tariffs on imported car parts can be mitigated for domestic manufacturers). CNN's Nathaniel Meyersohn contributed reporting. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
